Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-Dose Botulinum Toxin for Nocturnal Bruxism
NCT05620316Completed
- Sponsor
- Damascus University
- Start
- Mar 2021
- Primary completion
- Sep 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, double-blind trial of botulinum toxin type A in sleep-related bruxism (SB) (2 arms), sponsored by Damascus University. Primary endpoints: Change in the electromyographic recorded values at 6 months and Change in the perception of pain at 6 months. Started Mar 2021; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
sleep-related bruxism (SB)
Beyond the preview
Go deeper on NCT05620316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05620316.